http://www.law360.com/ Latest articles for organization: Teva Pharmaceutical Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/135395 Teva Pharmaceuticals USA Inc., having come out on the losing end in a three-year infringement struggle with Alcon Inc. over a patent related to the anti-bacterial eye drop drug Vigamox, has said it will keep up the fight in an appeal to the U.S. Court of Appeals for the Federal Circuit. http://www.law360.com/articles/135395 http://www.law360.com/articles/135307 A jury has sided with Novartis AG in a suit it filed claiming Teva Pharmaceuticals USA Inc. infringed the patent for its genital herpes drug Famvir by seeking regulatory approval to market its own generic version. http://www.law360.com/articles/135307 http://www.law360.com/articles/135185 The head of the European Commission's pharmaceutical task force reportedly told drug companies Thursday of plans to ask for details on patent deals with generic-drug makers that are suspected of delaying the entry of cheaper drugs into the market. http://www.law360.com/articles/135185 http://www.law360.com/articles/134825 Teva Pharmaceuticals Industries Ltd. has dropped claims for unfair competition and trade secrets misappropriation against Sandoz Inc. and parent company Novartis AG in a patent dispute over the multiple sclerosis drug Copaxone. http://www.law360.com/articles/134825 http://www.law360.com/articles/134805 Takeda Pharmaceutical Co. Ltd. is appealing its loss in a patent battle with Teva Pharmaceutical Industries Ltd. over a generic version of the acid reflux drug Prevacid. http://www.law360.com/articles/134805 http://www.law360.com/articles/133989 Cephalon Inc. and Barr Pharmaceuticals LLC have called a truce in their legal battles over the cancer painkiller Fentora. http://www.law360.com/articles/133989 http://www.law360.com/articles/134153 Teva Pharmaceuticals Ltd. has reportedly complained to the Federal Trade Commission that it has been unable to purchase bulk quantities of certain pharmaceuticals because brand-name drug companies are using a federal drug-safety program to unfairly limit competition. http://www.law360.com/articles/134153 http://www.law360.com/articles/133520 Teva Pharmaceutical Industries Ltd. plans to begin marketing a generic version of the acid reflux drug Prevacid now that a federal judge has ruled in its favor in a patent battle with Takeda Pharmaceutical Co. Ltd. http://www.law360.com/articles/133520 http://www.law360.com/articles/131860 The U.S. Supreme Court has had two recent opportunities to address federal preemption of state law claims regarding allegedly defective medical devices and prescription drugs. At first blush, these opinions may appear to send conflicting messages about the extent to which federal law preempts state common-law tort claims in these areas; however, one might argue that the different outcomes stem from the differences in the separate regulatory approval processes that govern devices and drugs, say James Zeszutek, J.J. Richardson, Melanie Jones and Randal Whitlatch of Dinsmore & Shohl LLP. http://www.law360.com/articles/131860 http://www.law360.com/articles/133341 Biovail Corp. has fired back in a lawsuit over its generic formulation of cholesterol treatment TriCor, alleging that the patents for TriCor owned by Elan Pharma International Ltd. and Fournier Laboratories Ireland Ltd. are invalid. http://www.law360.com/articles/133341 http://www.law360.com/articles/133249 Merck & Co. has responded to an early finding from the U.S. Patent and Trademark Office that its patent covering blockbuster asthma and allergy drug Singulair is invalid, although it may be too late to affect the pharmaceutical giant's ongoing feud with generics maker Teva Pharmaceutical Industries Ltd. http://www.law360.com/articles/133249 http://www.law360.com/articles/132977 Takeda Pharmaceutical Co. Ltd. has filed an infringement action to prevent Teva Pharmaceutical Industries Inc. from marketing a generic version of Rozerem, a prescription sleeping medication. http://www.law360.com/articles/132977 http://www.law360.com/articles/132544 The U.S. Department of Justice has named Leonard Grunstein, head of two real estate practice groups at Troutman Sanders LLP, as a defendant in a civil complaint in the still-unfolding case involving nursing home drug supply giant Omnicare Inc., which agreed Tuesday to pay $98 million to settle claims that it was part of a broad kickback scheme. http://www.law360.com/articles/132544 http://www.law360.com/articles/132454 Shire LLC has settled yet another patent infringement suit involving Carbatrol, this time by granting Apotex Inc. a license that will allow it to sell its own generic version of the epilepsy drug. http://www.law360.com/articles/132454 http://www.law360.com/articles/132144 Nursing home pharmacy giant Omnicare Inc. has agreed to shell out $98 million and a Teva Pharmaceutical Industries Ltd. unit has agreed to pay $14 million to settle claims that they were part of a wide-scale kickback conspiracy. http://www.law360.com/articles/132144 http://www.law360.com/articles/132090 Twin patent lawsuits brought by Hoffmann-La Roche Inc. accusing generic-drug maker Teva Pharmaceuticals USA Inc. and its Gate Pharmaceuticals division of infringing patents related to a popular osteoporosis drug have been dismissed because Teva dropped an application to make generic Boniva. http://www.law360.com/articles/132090 http://www.law360.com/articles/131102 Warner Chilcott PLC's allegations that Lupin Ltd. has infringed patents for its birth control drugs Loestrin 24 Fe and Femcon Fe will move forward in the U.S. District Court for the District of Delaware, now that the company has dropped identical protective suits in another court. http://www.law360.com/articles/131102 http://www.law360.com/articles/131475 British drugmaker Shire PLC has received a subpoena from U.S. investigators seeking documents related to the sales and marketing of three drugs, including Adderall, the company said. http://www.law360.com/articles/131475 http://www.law360.com/articles/131390 Abbott Laboratories has launched another suit seeking to block a generic version of its cholesterol drug TriCor, this one targeting generics maker Impax Laboratories Inc. http://www.law360.com/articles/131390 http://www.law360.com/articles/130896 A unit of specialty pharmaceutical firm Watson Pharmaceuticals Inc. has struck a deal with Barr Pharmaceuticals Inc. that resolves patent litigation over Watson’s Oxytrol and grants Barr a license to eventually market a generic version of the overactive bladder treatment. http://www.law360.com/articles/130896